Anlotinib Combined With Penpulimab as Front-line Treatment in Advanced Non-small Cell Lung Cancer - Trial NCT06341530
Access comprehensive clinical trial information for NCT06341530 through Pure Global AI's free database. This Phase 2 trial is sponsored by The First Affiliated Hospital of Zhengzhou University and is currently Recruiting. The study focuses on Non-small Cell Lung Cancer. Target enrollment is 33 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
The First Affiliated Hospital of Zhengzhou University
Timeline & Enrollment
Phase 2
Jan 31, 2024
Dec 31, 2025
Primary Outcome
Progression-free survival
Summary
In recent years, with the emergence and clinical application of anti-angiogenesis therapy,
 the therapeutic effect of patients has been significantly improved while ensuring that the
 adverse reactions of patients do not increase. Anti-angiogenic therapy can improve the
 hypoxia state of tumor tissue, normalize blood vessels, relieve immune suppression in tumor
 microenvironment, increase the degree of infiltration of immune cells, and fully activate
 immune cells to achieve the effect of tumor immunity. Previous studies have shown that
 penpulimab injection combined with anlotinib in the treatment of NSCLC can induce the
 normalization of tumor blood vessels and reshape the tumor immunosuppressive
 microenvironment, and the combination of the two can have synergistic effects.
 
 This study intends to treat patients with advanced non-small cell lung cancer (NSCLC)
 confirmed by pathology with the combination of anlotinib and penpulimab injection, and
 observe the efficacy and safety of anlotinib and penpulimab injection in the first and second
 lines of NSCLC. This study is expected to provide a reference for the treatment strategy of
 advanced non-small cell lung cancer patients, and has important clinical value for the
 treatment of advanced lung cancer.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT06341530
Non-Device Trial